The tweet was deleted by the author.
But we saved everything 🙂.
Zymeworks reports third quarter 2026 financial results after stock ends session up 3.9%
Zymeworks reported third quarter 2026 financial results. The stock is up 3.9% on the day at $30.81.
Highlights
- Zymeworks reported third quarter 2026 results and updated on business progress in the biotechnology segment with 231 employees.
- All 52 analysts covering Zymeworks stock rate it a buy, with a median price target of $38.
- Zymeworks stock is up 3.9% on the day at $30.81, with the company valued near $1.73 billion.
Zymeworks management reported third quarter 2026 financial results. The company also provided an update on its financial performance and business progress. Zymeworks operates in biotechnology and employs 231 people.
View post on X Loading...
Bullish structure supports shares as pullback momentum stalls
The session opened with a gap up from the previous close of $29.63 to $30, setting a bullish tone. Shares of Zymeworks are being supported by a daily structure that remains clearly bullish, with price holding above its MA-20, MA-50, and MA-200. The nearest resistance comes in at the weekly high of $31.45. Stoch RSI is nearing oversold territory, suggesting the recent pullback may be getting stretched and limiting further downside.
Upside probability dominates as traders focus on the weekly high
Traders should watch whether price closes above the weekly high at $31.45 to confirm continued buying interest. The day began with price jumping from $29.63 to $30 on the open. From here, the past week has seen a sustained move higher with a firm trend, but for the coming trading week, the probability of further upside is more than 80%, while the chance of downside is less than 20%, with an expected trading range of $29.44 to $32.17. A close above the weekly high would indicate buyers are committed to the advance, while a drop below $28.4 would signal the move is being faded. On the weekly chart, the longer-term picture stays firmly constructive.
Previously it was reported that analysts viewed Zymeworks' technical setup as bullish following the unveiling of preclinical data for its new CD3 multispecific T cell engager, ZW1953. The latest quarterly results and continued price strength reinforce this positive technical bias, with traders advised to watch the $31.45 weekly high as the next key inflection point.
This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Subscribe to TU news
Did you like the article?
Top News
Top 5 companies for you
United States
-
Afghanistan
-
Albania
-
Algeria
-
Angola
-
Argentina
-
Armenia
-
Australia
-
Austria
-
Azerbaijan
-
Bahamas
-
Bahrain
-
Bangladesh
-
Belarus
-
Belgium
-
Bolivia
-
Botswana
-
Brazil
-
Brunei
-
Bulgaria
-
Cambodia
-
Cameroon
-
Canada
-
Chile
-
China
-
Colombia
-
Congo
-
Costa Rica
-
Cote d'Ivoire
-
Croatia
-
Cuba
-
Cyprus
-
Czechia
-
DR Congo
-
Denmark
-
Dominican Republic
-
Ecuador
-
Egypt
-
El Salvador
-
Estonia
-
Eswatini
-
Ethiopia
-
Finland
-
France
-
Georgia
-
Germany
-
Ghana
-
Greece
-
Haiti
-
Hong Kong
-
Hungary
-
India
-
Indonesia
-
Iran, Islamic republic
-
Iraq
-
Ireland
-
Israel
-
Italy
-
Jamaica
-
Japan
-
Jordan
-
Kazakhstan
-
Kenya
-
Korea
-
Kuwait
-
Kyrgyzstan
-
Laos
-
Latvia
-
Lebanon
-
Lesotho
-
Libya
-
Lithuania
-
Luxembourg
-
Madagascar
-
Malaysia
-
Malta
-
Mauritius
-
Mexico
-
Moldova
-
Mongolia
-
Montenegro
-
Morocco
-
Mozambique
-
Myanmar
-
Namibia
-
Nepal
-
Netherlands
-
New Zealand
-
Nigeria
-
North Macedonia
-
Norway
-
Oman
-
Pakistan
-
Palestine
-
Panama
-
Papua New Guinea
-
Paraguay
-
Peru
-
Philippines
-
Poland
-
Portugal
-
Puerto Rico
-
Qatar
-
Reunion
-
Romania
-
Rwanda
-
Saudi Arabia
-
Serbia
-
Singapore
-
Slovakia
-
Slovenia
-
Somalia
-
South Africa
-
Spain
-
Sri Lanka
-
Sweden
-
Switzerland
-
Syria
-
Taiwan
-
Tajikistan
-
Tanzania
-
Thailand
-
Trinidad and Tobago
-
Tunisia
-
Turkey
-
UAE
-
Uganda
-
Ukraine
-
United Kingdom
-
United States
-
Uruguay
-
Uzbekistan
-
Venezuela
-
Vietnam
-
Yemen
-
Zambia
-
Zimbabwe
- Forex
- Crypto
Live News
